Baader Bank Aktiengesellschaft Invests $781,000 in Theravance Biopharma, Inc. $TBPH

Baader Bank Aktiengesellschaft bought a new stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 53,500 shares of the biopharmaceutical company’s stock, valued at approximately $781,000. Baader Bank Aktiengesellschaft owned approximately 0.11% of Theravance Biopharma as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently bought and sold shares of TBPH. Geode Capital Management LLC increased its position in Theravance Biopharma by 0.4% during the 2nd quarter. Geode Capital Management LLC now owns 893,983 shares of the biopharmaceutical company’s stock worth $9,863,000 after purchasing an additional 3,416 shares in the last quarter. Bank of America Corp DE grew its stake in Theravance Biopharma by 16.5% in the 2nd quarter. Bank of America Corp DE now owns 539,645 shares of the biopharmaceutical company’s stock worth $5,952,000 after acquiring an additional 76,417 shares during the period. Assenagon Asset Management S.A. grew its stake in Theravance Biopharma by 1,629.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 414,715 shares of the biopharmaceutical company’s stock worth $6,055,000 after acquiring an additional 390,735 shares during the period. BNP Paribas Financial Markets lifted its stake in shares of Theravance Biopharma by 30.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 387,472 shares of the biopharmaceutical company’s stock worth $4,274,000 after purchasing an additional 91,300 shares during the period. Finally, Acadian Asset Management LLC boosted its holdings in shares of Theravance Biopharma by 76.8% during the second quarter. Acadian Asset Management LLC now owns 308,652 shares of the biopharmaceutical company’s stock worth $3,401,000 after purchasing an additional 134,058 shares during the last quarter. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on TBPH shares. HC Wainwright lifted their price target on Theravance Biopharma from $15.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday, November 11th. BTIG Research reiterated a “buy” rating and issued a $40.00 price target on shares of Theravance Biopharma in a report on Tuesday, February 3rd. Oppenheimer began coverage on Theravance Biopharma in a research report on Wednesday, December 3rd. They set an “outperform” rating and a $27.00 price target for the company. Weiss Ratings restated a “hold (c)” rating on shares of Theravance Biopharma in a research note on Thursday, January 22nd. Finally, Wall Street Zen lowered Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $27.80.

Insider Activity at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 31,067 shares of the firm’s stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $18.75, for a total transaction of $582,506.25. Following the completion of the sale, the senior vice president owned 277,695 shares of the company’s stock, valued at approximately $5,206,781.25. This trade represents a 10.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 6.90% of the company’s stock.

Theravance Biopharma Price Performance

Theravance Biopharma stock opened at $19.51 on Thursday. Theravance Biopharma, Inc. has a 12-month low of $7.90 and a 12-month high of $21.03. The company has a market capitalization of $988.57 million, a price-to-earnings ratio of 34.23 and a beta of 0.15. The firm’s fifty day moving average price is $19.10 and its 200 day moving average price is $16.14.

Theravance Biopharma (NASDAQ:TBPH) last announced its earnings results on Monday, November 10th. The biopharmaceutical company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.10. The business had revenue of $19.99 million for the quarter, compared to analyst estimates of $19.89 million. Theravance Biopharma had a return on equity of 12.20% and a net margin of 36.53%. Analysts forecast that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current fiscal year.

Theravance Biopharma Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.